Table 4 Assessing the Impact of Risankizumab on Body Surface Area Reduction in Psoriasis Patients: A Multiple Linear Regression Analysis
Variable | β-regression coefficient | p-value | 95% Confidence Interval (CI) |
|---|---|---|---|
Risankizumab vs. Adalimumab | 34.119 | 0.1687 | –14.926–83.166 |
Age | –1.408 | 0.1447 | –3.314–0.499 |
Female vs. male | 29.19 | 0.205 | –16.438–74.819 |
Duration of illness | 0.909 | 0.504 | –1.801–3.619 |
Duration of treatment | –0.624 | 0.937 | –16.382–15.135 |
Number of comorbidities | 2.197 | 0.804 | –15.441–19.836 |